Abstract

Predicting novel uses for drugs using their chemical, pharmacological, and indication information contributes to minimizing costs and development periods. Most previous prediction methods focused on integrating the similarity and association information of drugs and diseases. However, they tended to construct shallow prediction models to predict drug-associated diseases, which make deeply integrating the information difficult. Further, path information between drugs and diseases is important auxiliary information for association prediction, while it is not deeply integrated. We present a deep learning-based method, CGARDP, for predicting drug-related candidate disease indications. CGARDP establishes a feature matrix by exploiting a variety of biological premises related to drugs and diseases. A novel model based on convolutional neural network (CNN) and gated recurrent unit (GRU) is constructed to learn the local and path representations for a drug-disease pair. The CNN-based framework on the left of the model learns the local representation of the drug-disease pair from their feature matrix. As the different paths have discriminative contributions to the drug-disease association prediction, we construct an attention mechanism at the path level to learn the informative paths. In the right part, a GRU-based framework learns the path representation based on path information between the drug and the disease. Cross-validation results indicate that CGARDP performs better than several state-of-the-art methods. Further, CGARDP retrieves more real drug-disease associations in the top part of the prediction result that are of concern to biologists. Case studies on five drugs demonstrate that CGARDP can discover potential drug-related disease indications.

Highlights

  • There has been a gradual increase in new molecular entity research and development, but the number of new molecular entities approved by the Food and Drug Administration (FDA) has been decreasing [1,2,3]

  • We propose a prediction method based on a convolutional neural network (CNN) and gated recurrent unit (GRU)

  • To predict the potential representation of the association between a drug and a disease, we propose a novel prediction model based on a CNN and GRU

Read more

Summary

Introduction

There has been a gradual increase in new molecular entity research and development, but the number of new molecular entities approved by the Food and Drug Administration (FDA) has been decreasing [1,2,3]. Traditional drug development often requires 10–15 years and an investment of $1.5 billion [4,5,6]. Because FDA-approved drugs undergo biological experiments, clinical trials, and are evaluated for safety, drugs are often repositioned. Repositioning existing drugs for new indications or uses requires only 6.5 years, and the cost is $300 million, which is far less than the cost of developing a new drug [7,8,9]. Based on different biological premises and assumptions, researchers use different data types and biological preconditions to study drug repositioning. Research methods include retargeting based on Molecules 2019, 24, 2712; doi:10.3390/molecules24152712 www.mdpi.com/journal/molecules

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call